Guy Neff

Summary

Affiliation: University of Cincinnati
Country: USA

Publications

  1. ncbi Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease
    Guy W Neff
    Department of Medicine, University of Miami, Florida, USA
    Am J Gastroenterol 97:2117-9. 2002
  2. ncbi Acquired hyperplastic gastric polyps in solid organ transplant patients
    Rafael Amaro
    Department of Medicine, University of Miami School of Medicine, Florida 33136, USA
    Am J Gastroenterol 97:2220-4. 2002
  3. ncbi Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease
    Guy W Neff
    Department of Medicine, Division of GI Transplant, University of Miami, Miami, FL 33136, USA
    Liver Transpl 9:239-47. 2003
  4. ncbi Survival of human immunodeficiency virus-infected liver transplant recipients
    Margaret V Ragni
    Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 4306, USA
    J Infect Dis 188:1412-20. 2003
  5. ncbi Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade
    Guy W Neff
    Center for Liver Diseases, Department of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA
    Liver Transpl 10:1372-8. 2004
  6. ncbi Sirolimus-associated hepatotoxicity in liver transplantation
    Guy W Neff
    University of Cincinnati, Cincinnati, OH, USA
    Ann Pharmacother 38:1593-6. 2004
  7. ncbi Consumption of dietary supplements in a liver transplant population
    Guy W Neff
    Department of Medicine, Surgery and Nutrition, University of Miami, Miami, FL, USA
    Liver Transpl 10:881-5. 2004
  8. ncbi Topical testosterone treatment for chronic allograft failure in liver transplant recipients with recurrent hepatitis C virus
    G W Neff
    University of Cincinnati, School of Medicine, Cincinnati, Ohio 45267 0595, USA
    Transplant Proc 36:3071-4. 2004
  9. ncbi Outcomes among patients with end-stage liver disease who are coinfected with HIV and hepatitis C virus
    Guy W Neff
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Clin Infect Dis 41:S50-5. 2005
  10. ncbi Tenofovir therapy for lamivudine resistance following liver transplantation
    Guy W Neff
    College of Medicine, University of Cincinnati, 231 Albert Sabin Way, MSB Room 6560, Cincinnati, OH 45267 0595, USA
    Ann Pharmacother 38:1999-2004. 2004

Collaborators

Detail Information

Publications56

  1. ncbi Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease
    Guy W Neff
    Department of Medicine, University of Miami, Florida, USA
    Am J Gastroenterol 97:2117-9. 2002
    ..Delta-9-tetrahydrocannabinol may be an effective alternative in patients with intractable cholestatic pruritus...
  2. ncbi Acquired hyperplastic gastric polyps in solid organ transplant patients
    Rafael Amaro
    Department of Medicine, University of Miami School of Medicine, Florida 33136, USA
    Am J Gastroenterol 97:2220-4. 2002
    ..The exact cause of these polyps is unknown. The association with immunosuppressive therapy as well as the natural history of these acquired hyperplastic gastric polyps needs further investigation...
  3. ncbi Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease
    Guy W Neff
    Department of Medicine, Division of GI Transplant, University of Miami, Miami, FL 33136, USA
    Liver Transpl 9:239-47. 2003
    ..Given the complex pharmacologic interactions between the protease inhibitors and tacrolimus, careful monitoring, and attention is required to prevent toxicity or underdosing...
  4. ncbi Survival of human immunodeficiency virus-infected liver transplant recipients
    Margaret V Ragni
    Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 4306, USA
    J Infect Dis 188:1412-20. 2003
    ..Further prospective studies are warranted...
  5. ncbi Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade
    Guy W Neff
    Center for Liver Diseases, Department of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA
    Liver Transpl 10:1372-8. 2004
    ..In conclusion, pre-LTx HBV viremia should be considered in planning post-LTx prophylaxis. Trials to evaluate oral antiviral agents in combination with or without HBIg therapy are needed...
  6. ncbi Sirolimus-associated hepatotoxicity in liver transplantation
    Guy W Neff
    University of Cincinnati, Cincinnati, OH, USA
    Ann Pharmacother 38:1593-6. 2004
    ..Unlike tacrolimus and cyclosporine, it has no effect on calcineurin activity in liver transplant recipients...
  7. ncbi Consumption of dietary supplements in a liver transplant population
    Guy W Neff
    Department of Medicine, Surgery and Nutrition, University of Miami, Miami, FL, USA
    Liver Transpl 10:881-5. 2004
    ..The results of this report suggest that transplant teams need to question each recipient about the use of herbal and vitamin remedies and educate them regarding the potential hazards...
  8. ncbi Topical testosterone treatment for chronic allograft failure in liver transplant recipients with recurrent hepatitis C virus
    G W Neff
    University of Cincinnati, School of Medicine, Cincinnati, Ohio 45267 0595, USA
    Transplant Proc 36:3071-4. 2004
    ..We sought to determine whether topical testosterone therapy is associated with improved muscle mass and survival in patients with chronic allograft failure post-liver transplant...
  9. ncbi Outcomes among patients with end-stage liver disease who are coinfected with HIV and hepatitis C virus
    Guy W Neff
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Clin Infect Dis 41:S50-5. 2005
    ..Clinical and serological markers of ESLD in coinfected patients, management of cirrhosis, and the appropriateness of transplantation are discussed...
  10. ncbi Tenofovir therapy for lamivudine resistance following liver transplantation
    Guy W Neff
    College of Medicine, University of Cincinnati, 231 Albert Sabin Way, MSB Room 6560, Cincinnati, OH 45267 0595, USA
    Ann Pharmacother 38:1999-2004. 2004
    ..Resistant hepatitis B virus (HBV) strains develop in 30% of liver transplant recipients treated with lamivudine within 2 years from the time of transplantation...
  11. ncbi Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy
    Guy W Neff
    Center for Liver Diseases, Division of GI Transplant, Department of Medicine, University of Miami, Miami, FL, USA
    Transplantation 78:1303-7. 2004
    ..We present data from a retrospective review in liver-transplant recipients suffering from HCV recurrence that were treated with pegylated alpha-2b interferon and ribavirin...
  12. ncbi Review article: current status of liver transplantation in HIV-infected patients
    G W Neff
    Division of Digestive Diseases, University of Cincinnati, OH, USA
    Aliment Pharmacol Ther 20:993-1000. 2004
    ..This review will discuss the current clinical status of liver transplantation in individuals suffering from human immunodeficiency virus infection...
  13. ncbi The importance of clinical parameters when differentiating cholestatic hepatitis C virus from allograft rejection
    G W Neff
    Department of Medicine, University of Cincinnati, Cincinnati, Ohio 45267 0595, USA
    Transplant Proc 37:4397-402. 2005
    ..Our objective was to determine the diagnostic accuracy of clinical and histological parameters in liver transplant recipients with RHCV and concurrent cholestasis...
  14. ncbi Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin
    Guy W Neff
    Department of Medicine, Division of Digestive Diseases, University of Cincinnati, Cincinnati, Ohio 45267, USA
    Dig Dis Sci 52:2497-500. 2007
    ..The aim of this review is to investigate the safety and efficacy of converting HBIg and LAM therapy to ADV and LAM therapy...
  15. ncbi Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series
    Guy Neff
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    Liver Transpl 16:960-3. 2010
    ..These findings suggest that rifaximin may be effective for the treatment of recurrent CDI and may provide a therapeutic option for CDI in immunocompromised patients...
  16. ncbi Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy
    G W Neff
    Department of Medicine, University of Cincinnati, Cincinnati, Ohio 45267 0595, USA
    Transplant Proc 38:3552-5. 2006
    ..We report hospital admission rates and economic impact of patients with end-stage liver disease suffering from hepatic encephalopathy...
  17. ncbi Intestinal and multivisceral transplantation after abdominal trauma
    Seigo Nishida
    Division of Transplantation, Department of Surgery, University of Miami, Jackson Memorial Center, Miami, Florida 33101. USA
    J Trauma 56:323-7. 2004
    ..CONCLUSION Intestinal and multivisceral transplantation are viable options for the treatment of irreversible intestinal failure associated with severe trauma. Surviving patients are TPN independent and have a satisfactory quality of life...
  18. ncbi Ethnic differences in hepatocellular carcinoma: implications for liver transplantation
    Nyingi Kemmer
    University of Cincinnati, 231 Albert Sabin Way, MSB Room 6363, Cincinnati, OH 45267 0595, USA
    Dig Dis Sci 53:551-5. 2008
    ..Ethnicity was the only significant predictor for failure to meet MC. Significantly fewer Caucasians exceeded the MC compared to AA (44 vs. 71%; P = 0.0015). Conclusion AA are more likely to present with HCC that exceeds the MC...
  19. ncbi An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma
    Nyingi Kemmer
    Division of Digestive Diseases, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267 0595, USA
    Liver Transpl 12:1519-22. 2006
    ..These results demonstrate the poor correlation of serum AFP with the presence of HCC in patients awaiting liver transplantation...
  20. ncbi The long-term effects of immune suppression on liver transplant recipients with recurrent hepatitis C viral infection
    G W Neff
    University of Cincinnati, School of Medicine, Cincinnati, Ohio, USA
    Transplant Proc 36:3065-7. 2004
    ....
  21. ncbi Pharmacoeconomics of hepatic encephalopathy
    Guy Neff
    Digestive Disease Division, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267 0595, USA
    Pharmacotherapy 30:28S-32S. 2010
    ..One study found that rifaximin produced a cost savings/patient/year of more than $3000 over lactulose therapy...
  22. ncbi Factors affecting compliance and persistence with treatment for hepatic encephalopathy
    Guy Neff
    Digestive Disease Division, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267 0595, USA
    Pharmacotherapy 30:22S-7S. 2010
    ..Patients with cirrhosis and hepatic encephalopathy who are prescribed lactulose experience a greater frequency of adverse effects, require more hospitalizations, and suffer more disease recurrence than those prescribed rifaximin...
  23. ncbi Malignancy in pediatric transplant recipients
    Joseph F Buell
    The Israel Penn International Transplant Tumor Registry, Division of Transplantation, University of Cincinnati, Cincinnati, Ohio 45267, USA
    Semin Pediatr Surg 15:179-87. 2006
    ..This leaves transplant physicians with several new and novel immunosuppressive agents with uncertain oncologic potentials that will need to be examined over the next decade...
  24. ncbi Long-term analysis of primary nonfunction in liver transplant recipients
    N Kemmer
    Department of Internal Medicine, Division of Digestive Disease, University of Cincinnati, Cincinnati, OH 45267 0595, USA
    Transplant Proc 39:1477-80. 2007
    ..In conclusion, there has been decreased incidence of PNF among liver transplant recipients in the last decade...
  25. ncbi Donor intracaval thrombus formation and pulmonary embolism after simultaneous piggyback liver transplantation and aortic valve replacement
    Seigo Nishida
    Division of Transplantation, Department of Surgery, University of Miami Jackson Memorial Medical Center, Miami, FL, USA
    Clin Transplant 17:465-8. 2003
    ..The current case should alert clinicians to think of a donor intracaval thrombus as a complication of PB liver transplantation and a possible source of PE...
  26. ncbi Intestinal schistosomiasis following orthotopic liver transplantation: a case report
    K Ahmed
    Department of Digestive Diseases, University of Cincinnati, Cincinnati, Ohio 45267, USA
    Transplant Proc 39:3502-4. 2007
    ..Posttransplant recurrence of schistosomiasis has rarely been described. We report a case of posttransplant recurrence of schistosomiasis...
  27. ncbi Alpha-1-antitrypsin deficiency: outcomes after liver transplantation
    N Kemmer
    Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio 45267, USA
    Transplant Proc 40:1492-4. 2008
    ..51). By regression analysis, age was the only predictor for patient survival (P = .04). In conclusion, adult and pediatric LT recipients with AAT are predominantly of Caucasian ethnicity and have an excellent post-LT survival...
  28. ncbi Acquired platelet dysfunction with spontaneous intramuscular hematoma and compartment syndrome in cirrhosis
    U Navaneethan
    Department of Internal Medicine, University of Cincinnati College of Medicine, OH, USA
    Minerva Gastroenterol Dietol 54:445-9. 2008
    ..This case highlights many of the common coagulation abnormalities seen in cirrhosis. The authors speculate the sequence of events in our patient at every level of the coagulation cascade which could have lead to this fatal outcome...
  29. ncbi Liver transplantation for primary and metastatic hepatic malignancy: a single center experience
    Amit D Tevar
    Division of Transplantation, Department of Surgery, University of Cincinnati, Ohio 45267-0558, USA
    Surgery 139:535-41. 2006
  30. ncbi Ten years of sirolimus therapy in orthotopic liver transplant recipients
    G W Neff
    University of Miami, Miami, Florida, USA
    Transplant Proc 35:209S-216S. 2003
    ..However, reports of sirolimus related side effects have decreased the transplant communities' enthusiasm towards promoting this agent as a safe immune suppression agent...
  31. ncbi Management of hypertension in liver transplant patients
    Syed A Najeed
    Dayton VA Medical Center, Dayton, OH, USA
    Int J Cardiol 152:4-6. 2011
    ..Treatment of post liver transplantation hypertension in patients with co-morbid conditions such as coronary artery disease, diabetes mellitus, congestive heart failure, and renal disease will likely require combination therapy...
  32. ncbi The impact of a change in tacrolimus monitoring immunoassay techniques on clinical decision making
    Teresa M Cavanaugh
    University of Cincinnati, University Hospital, Ohio 45267 0004, USA
    Prog Transplant 20:350-6. 2010
    ..Tacrolimus is an immunosuppressant that undergoes therapeutic drug monitoring. The laboratory at our institution changed its immunoassay techniques from the fluorescence polarization immunoassay to the cloned enzyme donation immunoassay...
  33. ncbi Therapy related CMML: a case report and review of the literature
    Faheem Ahmed
    Department of Internal Medicine, Hematology and Medical Oncology Division, University of Cincinnati, Cincinnati, OH, USA
    Int J Hematol 89:699-703. 2009
    ..This is the first a case of t-CMML reported in a liver transplant recipient. In this article, we also summarize all reported cases of t-CMML, and we review therapy related MDS in recipients of solid organ transplant...
  34. ncbi Outcomes in adult and pediatric liver transplantation among various ethnic groups
    G W Neff
    Department of Medicine, University of Cincinnati, Cincinnati, Ohio 45267 0595, USA
    Transplant Proc 39:3204-6. 2007
    ..The aim of this study was to evaluate the impact of ethnicity on patient and graft survivals among adult and pediatric patients...
  35. ncbi Prediction of survival outcome of ICU patients awaiting orthotopic liver transplantation
    A Sobhonslidsuk
    Center for Liver Diseases, University of Miami, Miami, Florida 33136, USA
    Transplant Proc 34:1223-5. 2002
  36. ncbi Liver transplant for the septuagenarians: importance of patient selection
    K Safdar
    Center for Liver Diseases, Department of Medicine, Division of GI Transplant, University of Miami, Miami, Florida 33136, USA
    Transplant Proc 36:1445-8. 2004
    ..010, respectively). These results suggest that in this group of patients UNOS status classification, CIT and WIT correlate with survival. The sample size was too small to derive a conclusion about the association with the MELD score...
  37. ncbi Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience
    E S Woodle
    University of Cincinnati, Cincinnati, Ohio, USA
    Transplant Proc 37:958-9. 2005
    ..PCA recurrence rates are relatively low in patients who initially presented with stage I and II disease, and are half that of patients with stage III disease...
  38. ncbi Refractory ascites after liver transplantation: an analysis of 1058 liver transplant patients at a single center
    S Nishida
    Division of Transplantation, Department of Surgery, University of Miami Jackson Memorial Medical Center, Miami, Florida, USA
    Am J Transplant 6:140-9. 2006
    ..This study illustrates the importance of developing an optimal treatment strategy to (i) effectively treat RA if it develops and (ii) prevent hepatitis C recurrence...
  39. ncbi Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency
    G W Neff
    University of Miami, Miami, Florida, USA
    Transplant Proc 35:3029-31. 2003
    ..CONCLUSION: This retrospective review suggests that OLT patients suffering from tacrolimus-related renal insufficiency successfully converted to sirolimus may benefit from this therapy...
  40. ncbi Fulminant hepatic failure from herpes simplex virus: post liver transplantation acyclovir therapy and literature review
    M Montalbano
    University of Cincinnati, Division for Digestive Diseases, Cincinnati, Ohio, USA
    Transplant Proc 37:4393-6. 2005
    ..CONCLUSION: Treatment of HSV fulminant hepatitis is dependent up on early suspicion and prompt intervention. In addition, antiviral therapy may need to be lifelong...
  41. ncbi Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain rea
    Guy W Neff
    Center for Liver Diseases and Division of GI Transplant, Department of Medicine, University of Miami, FL 33136, USA
    Liver Transpl 10:595-8. 2004
    ..In conclusion, direct detection of HCV RNA by RT-PCR of liver tissue appears to more effectively predict SVR following pegylated interferon and ribavirin therapy than the conventional use of serum...
  42. ncbi A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection
    Guy W Neff
    University of Miami, Department of Medicine, Miami, FL 33136, USA
    Liver Transpl 9:477-83. 2003
    ..Recombinant erythropoietin was started in 5 of 21 patients. Sirolimus serum levels were found to be greater than 20 ng/dL in 12 patients. Sirolimus was discontinued in 9 patients,..
  43. ncbi Liver transplantation trends for older recipients: regional and ethnic variations
    Nyingi Kemmer
    University of Cincinnati, Cincinnati, OH 45267 0595, USA
    Transplantation 86:104-7. 2008
    ..The aim of this study was to describe the transplantation trends in the older recipient (older than 65 years)...
  44. ncbi A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications
    Marzia Montalbano
    Division of Hepatology, Department of Medicine, University of Miami School of Medicine, Miami, FL, USA
    Transplantation 78:264-8. 2004
    ..CONCLUSIONS: SRL is a powerful immunosuppressant but not devoid of side effects. These results have elevated our level of suspicion when instituting SRL and may help with early recognition and prevention of drug related complications...
  45. ncbi Impact of geographic location on access to liver transplantation among ethnic minorities
    Nyingi Kemmer
    Division of Digestive Diseases, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267 0595, USA
    Transplantation 85:166-70. 2008
    ..Therefore, the aim of this study was to determine ethnic transplantation trends based on United Network for Organ Sharing (UNOS) regions...
  46. ncbi Management of recurrent viral hepatitis B and C after liver transplantation
    Marzia Montalbano
    University of Cincinnati, 231 Albert Sabin Way, MSB Room 6560, Cincinnati, OH 45267-0595, USA
    Curr Gastroenterol Rep 8:60-6. 2006
    ..This review investigates the up-to-date information on treatment outcomes for HCV and HBV in the period following liver transplant...
  47. ncbi Revisiting posttransplant survival for hepatitis C virus recipients
    Nyingi Kemmer
    Division of Digestive Diseases, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA
    Transplantation 84:932-3. 2007
    ..79). This comparative analysis of posttransplant outcomes for HCV recipients suggests an improvement in graft survival in the latter years...
  48. ncbi Managing chronic hepatitis C in the difficult-to-treat patient
    Nyingi Kemmer
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    Liver Int 27:1297-310. 2007
    ..This article reviews the risk factors for HCV treatment resistance and discusses the assessment and management of difficult-to-treat patients...
  49. ncbi Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection
    Guy W Neff
    University of Cincinnati, Ohio, USA
    Liver Transpl 10:1497-503. 2004
    ..As the allograft shortage continues, the optimal use of cadaveric livers continues to be of primary importance. The use of deceased donor livers in patients with allograft failure caused by HCV remains a highly controversial issue...
  50. ncbi Ethnic variations in chronic liver diseases
    Nyingi Kemmer
    University of Cincinnati, Cincinnati, OH 45267 0595, USA
    Dig Dis Sci 53:1339-44. 2008
    ..This review will discuss the ethnic variations and implications of the most common liver diseases...
  51. ncbi Sirolimus therapy in orthotopic liver transplant (OLT) recipients with acute renal insufficiency
    Marzia Montalbano
    Department of Medicine, University of Miami, Miami, Florida 33136, USA
    Dig Dis Sci 49:1986-9. 2004
  52. ncbi Rhabdomylysis transference during liver transplantation
    Muslim Atiq
    Transplantation 81:1359-60. 2006
  53. ncbi Successful treatment with thalidomide in a liver transplant recipient with giant esophageal ulcers
    Muslim Atiq
    Division of Digestive Diseases, University of Cincinnati, Cincinnati, Ohio 45267, USA
    Liver Transpl 12:987-8. 2006
  54. ncbi Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid
    Guy W Neff
    J Hepatol 41:1062-4. 2004
  55. ncbi Adult onset urea cycle disorder in a patient with presumed hepatic encephalopathy
    Muslim Atiq
    Division of Gastroenterology, University Hospital of Cincinnati, Cincinnati, OH, USA
    J Clin Gastroenterol 42:213-4. 2008
    ..We hereby present an interesting case that presented with hyperammonemia and encephalopathy; later found to have an urea cycle defect...
  56. ncbi Beneficial effects of topical testosterone replacement in patients with end-stage liver disease
    Guy W Neff
    Center for Liver Diseases, Division of GI Transplant, Department of Medicine, University of Miami, Miami, Florida, USA
    Dig Dis Sci 49:1186-9. 2004